Outset Medical (OM) Competitors

Carlsmed has lower revenue, but higher earnings than Outset Medical. Carlsmed is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.

Outset Medical currently has a consensus price target of $10.00, suggesting a potential upside of 102.84%. Carlsmed has a consensus price target of $19.25, suggesting a potential upside of 40.20%. Given Outset Medical's higher possible upside, equities analysts plainly believe Outset Medical is more favorable than Carlsmed.

In the previous week, Outset Medical and Outset Medical both had 9 articles in the media. Carlsmed's average media sentiment score of 0.52 beat Outset Medical's score of -0.06 indicating that Carlsmed is being referred to more favorably in the news media.

Carlsmed has a net margin of -57.42% compared to Outset Medical's net margin of -63.06%. Carlsmed's return on equity of -38.06% beat Outset Medical's return on equity.

40.8% of Electromed shares are owned by institutional investors. 10.5% of Electromed shares are owned by company insiders. Comparatively, 2.5% of Outset Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Electromed presently has a consensus target price of $37.50, indicating a potential downside of 11.93%. Outset Medical has a consensus target price of $10.00, indicating a potential upside of 102.84%. Given Outset Medical's higher possible upside, analysts clearly believe Outset Medical is more favorable than Electromed.

Electromed has higher earnings, but lower revenue than Outset Medical. Outset Medical is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Electromed has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Outset Medical has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market.

In the previous week, Outset Medical had 8 more articles in the media than Electromed. MarketBeat recorded 9 mentions for Outset Medical and 1 mentions for Electromed. Electromed's average media sentiment score of 1.54 beat Outset Medical's score of -0.06 indicating that Electromed is being referred to more favorably in the media.

Electromed has a net margin of 11.34% compared to Outset Medical's net margin of -63.06%. Electromed's return on equity of 15.71% beat Outset Medical's return on equity.

In the previous week, Treace Medical Concepts and Treace Medical Concepts both had 9 articles in the media. Treace Medical Concepts' average media sentiment score of 0.00 beat Outset Medical's score of -0.06 indicating that Treace Medical Concepts is being referred to more favorably in the media.

84.1% of Treace Medical Concepts shares are owned by institutional investors. 23.4% of Treace Medical Concepts shares are owned by insiders. Comparatively, 2.5% of Outset Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Treace Medical Concepts has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Outset Medical has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market.

Treace Medical Concepts has a net margin of -28.99% compared to Outset Medical's net margin of -63.06%. Outset Medical's return on equity of -58.06% beat Treace Medical Concepts' return on equity.

Treace Medical Concepts has higher revenue and earnings than Outset Medical. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.

Treace Medical Concepts currently has a consensus price target of $5.17, indicating a potential upside of 10.71%. Outset Medical has a consensus price target of $10.00, indicating a potential upside of 102.84%. Given Outset Medical's stronger consensus rating and higher probable upside, analysts clearly believe Outset Medical is more favorable than Treace Medical Concepts.

55.5% of Sight Sciences shares are owned by institutional investors. 30.4% of Sight Sciences shares are owned by insiders. Comparatively, 2.5% of Outset Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Sight Sciences had 5 more articles in the media than Outset Medical. MarketBeat recorded 14 mentions for Sight Sciences and 9 mentions for Outset Medical. Sight Sciences' average media sentiment score of 0.61 beat Outset Medical's score of -0.06 indicating that Sight Sciences is being referred to more favorably in the media.

Sight Sciences has a net margin of -35.69% compared to Outset Medical's net margin of -63.06%. Sight Sciences' return on equity of -43.39% beat Outset Medical's return on equity.

Sight Sciences has higher earnings, but lower revenue than Outset Medical. Sight Sciences is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.

Sight Sciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market. Comparatively, Outset Medical has a beta of 1.96, suggesting that its share price is 96% more volatile than the broader market.

Sight Sciences presently has a consensus target price of $7.88, suggesting a potential upside of 2.27%. Outset Medical has a consensus target price of $10.00, suggesting a potential upside of 102.84%. Given Outset Medical's higher possible upside, analysts plainly believe Outset Medical is more favorable than Sight Sciences.